Current Bids
Supply Chain Management
Sourcing & Contract Management
Request for Qualification
Bid Number #: 190147/ME
RFx Name: Finish Out Mid-Campus Building 1, Floors 19-24
RFx Information:
Open: Nov 18, 2019 5:00 PM
Close: Dec 18, 2019 2:00 PM
Contact Information:
Name: Mary E Mueller
Email: memuelle@mdanderson.org
Phone: 713.745.2102
The University of Texas MD Anderson Cancer Center
Finish Out Mid-Campus Building 1, Floors 19-24 - 190147/ME
Introduction to MD Anderson
MD Anderson is known throughout the world for high-quality cancer care, research, academic programs and prevention services. Since its establishment in 1941, MD Anderson has made major contributions to improve the outlook for cancer patients everywhere.
MD Anderson was one of the first three federally designated comprehensive cancer centers by the National Cancer Act of 1971. A survey of health professionals has routinely ranked MD Anderson as one of the two premier cancer centers in the nation for the past eight years. Over 55,000 persons annually seek care at MD Anderson. The team approach to cancer care, pioneered at MD Anderson, has been strengthened by consolidating specialty clinics into multi-disciplinary care centers that allow patients to receive more ambulatory care and treatment in a single location.
MD Anderson offers one of the largest bone marrow and stem cell transplantation programs, as well as clinical trials to improve existing therapies. Teams of clinical specialists collaborate with scientists on problems of common interest and test theories that shorten the application of better treatment methods. Translational research studies are responsible for the promising field of chemoprevention, which uses synthetic vitamins to reverse pre-malignant lesions and halt the recurrence of some cancers, and for innovative gene therapy strategies being evaluated for several forms ofcancer.
With faculty and staff working in more than 30 buildings in the greater Houston area and in central Texas, MD Anderson is the largest freestanding cancer center in the world. The physical plant covers more than 11 million square feet, featuring the latest equipment and facilities to support growing needs in outpatient and inpatient care, research, prevention and education. It includes inpatient hospital facilities with 571 beds.
Construction projects include the addition of 12 floors that can accommodate more than 300 new inpatient beds in Alkek Hospital on the North Campus; two new research buildings on the South Campus that will house the Center for Advanced Biomedical Imaging Research and Center for Targeted Therapy as part of the McCombs Institute; and MD Anderson's first facility on its Mid Campus, a 25-story building to support current office space and future growth needs.
In addition to its main campus in the Texas Medical Center and two research campuses in Bastrop County, Texas, MD Anderson has developed a number of local, national and international affiliations
RFx Overview
PROJECT DESCRIPTION, SCOPE AND BUDGET:
Owner seeks design-build services for its project number 190147, Finish Out Mid Campus Building 1, Floors 19-24. Under this project, Owner intends to finish out the remaining floors (19 through and including 24) of its Mid Campus Building 1 to help meet the institution’s office facility needs. This currently includes the finish out of approximately 250,000 gross square feet (GSF) of space that was left in a “shell condition” when the building was initially constructed.
The expected Design-Build Budget Limitation (DBBL) for the project is $35,300,000 (Thirty-Five Million Three Hundred Thousand Dollars).
For complete details regarding Project, please refer to posted RFQ, Section 2.2
PRE-SUBMITTAL CONFERENCE:
A pre-submittal conference will be held at the time and location described below.
DECEMBER 5, 2019, @ 2:00 PM LOCAL TIME
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
1MC BUILDING
7007 BERTNER AVENUE
CONF. ROOM 1MC Rooms 5 & 6
HOUSTON, TEXAS 77030
A guided tour of the project site will be included as a part of the conference agenda. Attendance at the pre-submittal conference is optional.
Questions related to this RFP must be sent via the information request form. All questions must be received no later than December 9, 2019 4:00 PM. Questions received after this time will not be accepted. Questions will not be answered via telephone. All answers to any questions or inquiries will be posted on the webpage for all Suppliers to access. It is the intent of MD Anderson to respond to all questions and concerns; however, MD Anderson shall reserve the right to decline to respond to any question or concern.
It is important to note that the supplier or suppliers selected to develop MD Anderson's RFP are not automatically qualified to engage with the Institution for purposes of implementing the recommended strategy or solutions. The engagement of contracted services for implementation can, at MD Anderson's discretion, be solicited via a second and separate Request for Proposal.
Standard Riders and Agreements
Addendum 1 PreSubmittal Conference location.pdf
Addendum 2 Sign In and HUB Tip Sheets.pdf
Addendum 3 Power Point Presentation.pdf
Addendum 4 RFI Questions and Answers.pdf
Addm 3 1MC Ph4 PreSubConf Dec.5.19.pptx
Attachment A Draft Agreement.pdf
Attachment A1 Agreement Exhibits.pdf
Attachment B HUB Policy Rider 104C Rev 11 2018.pdf
Attachment D Design Criteria Package.pdf
***Interested suppliers should also note that Subcontracting Opportunities are
probable in connection with this solicitation. Please review the HUB Subcontracting Tip Sheet
***RFx refers to RFP, RFQ, RFI, ITB, etc.